These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11488373)

  • 1. Negative symptoms of schizophrenia are improved by paroxetine added to neuroleptics: a pilot study.
    Jockers-Scherübl M; Godemann F; Pietzcker A
    J Clin Psychiatry; 2001 Jul; 62(7):573. PubMed ID: 11488373
    [No Abstract]   [Full Text] [Related]  

  • 2. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study.
    Jockers-Scherübl MC; Bauer A; Godemann F; Reischies FM; Selig F; Schlattmann P
    Int Clin Psychopharmacol; 2005 Jan; 20(1):27-31. PubMed ID: 15602113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Selective serotonin reuptake inhibitors in treatment of compulsive symptoms within the scope of schizophrenia].
    Scholl HP; Kasper S; Danos P; Höflich G; Möller HJ
    Nervenarzt; 1994 Jul; 65(7):478-81. PubMed ID: 7800092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features.
    Strous RD; Patel JK; Zimmet S; Green AI
    Am J Psychiatry; 1999 Jun; 156(6):973-4. PubMed ID: 10360153
    [No Abstract]   [Full Text] [Related]  

  • 5. Add-on fluvoxamine and negative symptoms of schizophrenia: analysis of data from augmentation studies in a single center.
    Silver H; Bilker WB
    J Clin Psychopharmacol; 2013 Oct; 33(5):710-1. PubMed ID: 23899641
    [No Abstract]   [Full Text] [Related]  

  • 6. Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms.
    Arango C; Kirkpatrick B; Buchanan RW
    J Nerv Ment Dis; 2000 Jan; 188(1):50-3. PubMed ID: 10665462
    [No Abstract]   [Full Text] [Related]  

  • 7. A case of social phobia with obsessive-compulsive symptoms improved by paroxetine in combination with risperidone.
    Yamauchi K; Ohta K; Taniguchi T; Ohmori T
    Gen Hosp Psychiatry; 2004; 26(3):242-3. PubMed ID: 15121355
    [No Abstract]   [Full Text] [Related]  

  • 8. Ziprasidone Augmentation of SSRI Antidepressants in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Pilot Study of Augmentation Therapy.
    Hamner MB; Hernandez-Tejada MA; Zuschlag ZD; Agbor-Tabi D; Huber M; Wang Z
    J Clin Psychopharmacol; 2019; 39(2):153-157. PubMed ID: 30640209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [SSRI antidepressants and negative schizophrenic symptoms: differences between paroxetine and fluvoxamine in patients treated with olanzapine].
    Rusconi AC; Carlone C; Muscillo M; Coccanari de' Fornari MA; Podda L; Piccione M
    Riv Psichiatr; 2009; 44(5):313-9. PubMed ID: 20066819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial.
    Takahashi H; Sugita T; Higuchi H; Shimizu T
    Hum Psychopharmacol; 2002 Mar; 17(2):95-8. PubMed ID: 12404698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluvoxamine for psychosis in Alzheimer's disease.
    Levkovitz Y; Bloch Y; Kaplan D; Diskin A; Abramovitchi I
    J Nerv Ment Dis; 2001 Feb; 189(2):126-9. PubMed ID: 11225688
    [No Abstract]   [Full Text] [Related]  

  • 12. Selective serotonin reuptake inhibitor modulation of clozapine effects on cognition in schizophrenia.
    Purdon SE; Snaterse M
    Can J Psychiatry; 1998 Feb; 43(1):84-5. PubMed ID: 9494753
    [No Abstract]   [Full Text] [Related]  

  • 13. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Cui X; Calabrese JR; Gao K;
    J Clin Psychopharmacol; 2011 Oct; 31(5):638-42. PubMed ID: 21869688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial.
    Anghelescu I; Szegedi A; Schlegel S; Weigmann H; Hiemke C; Wetzel H
    Eur Neuropsychopharmacol; 1998 Dec; 8(4):315-20. PubMed ID: 9928923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.
    Silver H
    Int Clin Psychopharmacol; 2003 Nov; 18(6):305-13. PubMed ID: 14571150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No effects of antidepressants on negative symptoms in schizophrenia.
    Hinkelmann K; Yassouridis A; Kellner M; Jahn H; Wiedemann K; Raedler TJ
    J Clin Psychopharmacol; 2013 Oct; 33(5):686-90. PubMed ID: 23857309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study.
    Wetzel H; Anghelescu I; Szegedi A; Wiesner J; Weigmann H; Härter S; Hiemke C
    J Clin Psychopharmacol; 1998 Feb; 18(1):2-9. PubMed ID: 9472836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacotherapy of chronic schizophrenic psychoses--neuroleptic plus serotonin reuptake inhibitor?].
    Salzmann E; Eikelmann B
    Psychiatr Prax; 1997 Sep; 24(5):253. PubMed ID: 9417552
    [No Abstract]   [Full Text] [Related]  

  • 19. Addition of risperidone to clozapine therapy in chronically psychotic inpatients.
    de Groot IW; Heck AH; van Harten PN
    J Clin Psychiatry; 2001 Feb; 62(2):129-30. PubMed ID: 11247102
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe weight gain induced by combination treatment with risperidone and paroxetine.
    Fukui H; Murai T
    Clin Neuropharmacol; 2002; 25(5):269-71. PubMed ID: 12410060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.